Insect cells as a production platform of complex virus-like particles

Expert Review of Vaccines

Volumn 12, Issue 2, 2013, Pages 225-236

  Fernandes, Fabiana ^a,b   Teixeira, Ana P ^a,b   Carinhas, Nuno ^a,b   Carrondo, Manuel J T ^a,b   Alves, Paula M ^a,b  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^b INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

Author keywords

baculovirus expression vector system; coinfection; insect cells; multicistronic vectors; stable expression; virus like particles

Indexed keywords

MULTIPROTEIN COMPLEX; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; WART VIRUS VACCINE;

BACULOVIRUS EXPRESSION SYSTEM; CELL POPULATION; DRUG SAFETY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INSECT CELL; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; ROTAVIRUS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; UTERINE CERVIX CANCER; VIRUS ENVELOPE; VIRUS GENOME; VIRUS LIKE AGENT;

ANIMALS; BACULOVIRIDAE; BIOTECHNOLOGY; CELL LINE; GENETIC VECTORS; INSECTS; VIRAL VACCINES; VIROSOMES;

EID: 84874045345     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.153     Document Type: Review

References (121)

1. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 6(3), 381-390 (2007).
2. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev. Vaccines 8(10), 1379-1398 (2009).
3. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 4(1), 5-12 (2008).
4. Garcia JM, Lai JC. Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update. Expert Rev. Anti. Infect. Ther. 9(4), 443-455 (2011).
5. Kirnbauer R, Chandrachud LM, O'Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219(1), 37-44 (1996).
6. Xiang J, Wünschmann S, George SL et al. Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays. J. Med. Virol. 68(4), 537-543 (2002).
7. Summers MD. Milestones leading to the genetic engineering of baculoviruses as expression vector systems and viral pesticides. Adv. Virus Res. 68, 3-73 (2006).
8. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Ther. 8(11), 846-854 (2001).
9. Hu YC. Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol. Sin. 26(4), 405-416 (2005).
10. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 23(5), 567-575 (2005).
11. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: A comparison of two insect cell lines as production platforms for influenza vaccines. Mol. Biotechnol. 45(3), 226-234 (2010).
12. Rhiel M, Mitchell-Logean CM, Murhammer DW. Comparison of Trichoplusia ni BTI-Tn-5B1-4 (high five) and Spodoptera frugiperda Sf-9 insect cell line metabolism in suspension cultures. Biotechnol. Bioeng. 55(6), 909-920 (1997).
13. Wang P, Granados RR, Shuler ML. Studies on serum-free culture of insect cells for virus propagation and recombinant protein production. J. Invert. Path. 59, 46-53 (1992).
14. Grace TD. Establishment of four strains of cells from insect tissues grown in vitro. Nature 195, 788-789 (1962).
15. Grace TD. Establishment of a line of cells from the silkworm Bombyx mori. Nature 216(5115), 613 (1967).
16. Hink WF. Established insect cell line from the cabbage looper, Trichoplusia ni. Nature 226(5244), 466-467 (1970).
17. Scotti PD. End-point dilution and plaque assay methods for titration of cricket paralysis virus in cultured Drosophila cells. J. Gen. Virol. 35(2), 393-396 (1977).
18. Grace TD. Insect tissue culture and its use in virus research. Adv. Virus Res. 14, 201-220 (1969).
19. Goodwin RH, Vaughn JL, Adams JR, Louloudes SJ. Replication of a nuclear polyhedrosis virus in an established insect cell line. J. Invertebr. Pathol. 16(2), 284-288 (1970).
20. Roldão A, Vieira HL, Charpilienne A et al. Modeling rotavirus-like particles production in a baculovirus expression vector system: infection kinetics, baculovirus DNA replication, mRNA synthesis and protein production. J. Biotechnol. 128(4), 875-894 (2007).
21. Mena JA, Ramírez OT, Palomares LA. Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles. BMC Biotechnol. 7, 39 (2007).
22. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 11(9), 438-444 (2003).
23. Roldao A, Silva AC, Mellado MCM, Alves PM, Carrondo MJ. Viruses and virus-like particles in biotechnology: fundamentals and applications. In: Comprehensive Biotechnology. Moo-Young M (Ed.). Elsevier, PA, USA 625-649 (2011).
24. Deschuyteneer M, Elouahabi A, Plainchamp D et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine. Human Vaccines 6(5), 407-419 (2010).
25. Bansal GP, Hatfield JA, Dunn FE et al. Candidate recombinant vaccine for human B19 parvovirus. J. Infect. Dis. 167(5), 1034-1044 (1993).
26. Brown CS, Van Lent JW, Vlak JM, Spaan WJ. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J. Virol. 65(5), 2702-2706 (1991).
27. Kajigaya S, Fujii H, Field A et al. Selfassembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc. Natl Acad. Sci. USA 88(11), 4646-4650 (1991).
28. Tsao EI, Mason MR, Cacciuttolo MA, Bowen SH, Folena-Wasserman G. Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses. Biotechnol. Bioeng. 49(2), 130-138 (1996).
29. Bräutigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 192(2), 512-524 (1993).
30. Urakawa T, Ferguson M, Minor PD et al. Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J. Gen. Virol. 70 (Pt 6), 1453-1463 (1989).
31. Chung YC, Huang JH, Lai CW et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J. Gastroenterol. 12(6), 921-927 (2006).
32. Hu YC, Hsu JT, Huang JH, Ho MS, Ho YC. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol. Lett. 25(12), 919-925 (2003).
33. Kibenge FS, Qian B, Nagy E, Cleghorn JR, Wadowska D. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can. J. Vet. Res. 63(1), 49-55 (1999).
34. Hu YC, Bentley WE. Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results. Biotechnol. Bioeng. 75(1), 104-119 (2001).
35. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol. 64(12), 5695-5700 (1990).
36. Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res. 21(5), 1219-1223 (1993).
37. Stewart M, Bhatia Y, Athmaran TN et al. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Vaccine 28(17), 3047-3054 (2010).
38. Pesavento JB, Crawford SE, Estes MK, Prasad BV. Rotavirus proteins: structure and assembly. Curr. Top. Microbiol. Immunol. 309, 189-219 (2006).
39. Zeng CQ, Labbé M, Cohen J et al. Characterization of rotavirus VP2 particles. Virology 201(1), 55-65 (1994).
40. Conner ME, Zarley CD, Hu B et al. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 174(Suppl. 1), S88-S92 (1996).
41. Crawford SE, Labbé M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol. 68(9), 5945-5952 (1994).
42. O'Neal CM, Crawford SE, Estes MK, Conner ME. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71(11), 8707-8717 (1997).
43. Vieira HL, Estêvão C, Roldão A et al. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J. Biotechnol. 120(1), 72-82 (2005).
44. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21(25-26), 3885-3900 (2003).
45. Parez N, Fourgeux C, Mohamed A et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J. Virol. 80(4), 1752-1761 (2006).
46. Nelson EA, Bresee JS, Parashar UD, Widdowson MA, Glass RI; Asian Rotavirus Surveillance Network. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 26(26), 3192-3196 (2008).
47. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 21(5-6), 361-367 (2003).
48. Palomares LA, González M, Ramírez OT. Evidence of Pluronic F-68 direct interaction with insect cells: impact on shear protection, recombinant protein, and baculovirus production. Enzyme Microb. Technol. 26(5-6), 324-331 (2000).
49. Peixoto C, Sousa MF, Silva AC, Carrondo MJ, Alves PM. Downstream processing of triple layered rotavirus like particles. J. Biotechnol. 127(3), 452-461 (2007).
50. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72(5), 3827-3836 (1998).
51. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75(13), 6154-6165 (2001).
52. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 576(1-2), 174-178 (2004).
53. Jeong SH, Qiao M, Nascimbeni M et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78(13), 6995-7003 (2004).
54. Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427-8432 (2007).
55. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA 100(11), 6753-6758 (2003).
56. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. Hepatol. 54(6), 1273-1285 (2011).
57. Taylor DR. Obstacles and advances in SARS vaccine development. Vaccine 24(7), 863-871 (2006).
58. Ho Y, Lin PH, Liu CY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem. Biophys. Res. Commun. 318(4), 833-838 (2004).
59. Lu X, Chen Y, Bai B et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 122(4), 496-502 (2007).
60. Buonaguro L, Buonaguro FM, Tornesello ML et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49(1), 35-47 (2001).
61. Ye L, Lin J, Sun Y et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 351(2), 260-270 (2006).
62. Warfield KL, Posten NA, Swenson DL et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis. 196(Suppl. 2), S421-S429 (2007).
63. Yang C, Ye L, Compans RW. Protection against filovirus infection: virus-like particle vaccines. Expert Rev. Vaccines 7(3), 333-344 (2008).
64. Sun Y, Carrion R Jr, Ye L et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383(1), 12-21 (2009).
65. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81(7), 3514-3524 (2007).
66. Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J. Invertebr. Pathol. 107(Suppl.), S31-S41 (2011).
67. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18(1), 244-251 (2005).
68. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50), 5751-5759 (2005).
69. Kang SM, Yoo DG, Lipatov AS et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4(3), e4667 (2009).
70. Wen Z, Ye L, Gao Y et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 84(3), 215-224 (2009).
71. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826-7834 (2011).
72. Haynes JR, Dokken L, Wiley JA et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27(4), 530-541 (2009).
73. Quan FS, Kim Y, Lee S et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J. Infect. Dis. 204(7), 987-995 (2011).
74. Kelly DC, Lescott T. Baculovirus replication: protein synthesis in Spodoptera frugiperda cells infected with Trichoplusia ni nuclear polyhedrosis virus. Mierobiologiea 4, 35-37 (1981).
75. Pijlman GP, Roode EC, Fan X et al. Stabilized baculovirus vector expressing a heterologous gene and GP64 from a single bicistronic transcript. J. Biotechnol. 123(1), 13-21 (2006).
76. Hitchman RB, Possee RD, Crombie AT et al. Genetic modification of a baculovirus vector for increased expression in insect cells. Cell Biol. Toxicol. 26(1), 57-68 (2010).
77. Kaba SA, Salcedo AM, Wafula PO, Vlak JM, van Oers MM. Development of a chitinase and v-cathepsin negative bacmid for improved integrity of secreted recombinant proteins. J. Virol. Methods 122(1), 113-118 (2004).
78. Possee RD, King LA. Baculovirus transfer vectors. Methods Mol. Biol. 388, 55-76 (2007).
79. Trowitzsch S, Bieniossek C, Nie Y, Garzoni F, Berger I. New baculovirus expression tools for recombinant protein complex production. J. Struct. Biol. 172(1), 45-54 (2010).
80. Bieniossek C, Imasaki T, Takagi Y, Berger I. MultiBac: expanding the research toolbox for multiprotein complexes. Trends Biochem. Sci. 37(2), 49-57 (2012).
81. Senger T, Schädlich L, Gissmann L, Müller M. Enhanced papillomavirus-like particle production in insect cells. Virology 388(2), 344-353 (2009).
82. Palmberger D, Wilson IB, Berger I, Grabherr R, Rendic D. SweetBac: A new approach for the production of mammalianised glycoproteins in insect cells. PLoS ONE 7(4), e34226 (2012).
83. Kato T, Murata T, Usui T, Park EY. Improvement of the production of GFPuv-?1,3-N-acetylglucosaminyl transferase 2 fusion protein using a molecular chaperone-assisted insect-cellbased expression system. Biotechnol. Bioeng. 89(4), 424-433 (2005).
84. Jarvis DL, Summers MD. Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirusinfected insect cells. Mol. Cell. Biol. 9(1), 214-223 (1989).
85. Guarino LA, Gonzalez MA, Summers MD. Complete Sequence and enhancer function of the homologous DNA regions of Autographa californica nuclear polyhedrosis virus. J. Virol. 60(1), 224-229 (1986).
86. Ishiyama S, Ikeda M. High-level expression and improved folding of proteins by using the vp39 late promoter enhanced with homologous DNA regions. Biotechnol. Lett. 32(11), 1637-1647 (2010).
87. Rankin C, Ooi BG, Miller LK. Eight base pairs encompassing the transcriptional start point are the major determinant for baculovirus polyhedrin gene expression. Gene 70(1), 39-49 (1988).
88. Guo L, Lu X, Kang SM, Chen C, Compans RW, Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313(2), 502-513 (2003).
89. Kang SM, Quan FS, Huang C et al. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 331(1), 20-32 (2005).
90. Marek M, van Oers MM, Devaraj FF, Vlak JM, Merten OW. Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol. Bioeng. 108(5), 1056-1067 (2011).
91. Caron AW, Archambault J, Massie B. High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system. Biotechnol. Bioeng. 36(11), 1133-1140 (1990).
92. Caron AW, Tom RL, Kamen AA, Massie B. Baculovirus expression system scaleup by perfusion of high-density Sf-9 cell cultures. Biotechnol. Bioeng. 43(9), 881-891 (1994).
93. Ikonomou L, Schneider YJ, Agathos SN. Insect cell culture for industrial production of recombinant proteins. Appl. Microbiol. Biotechnol. 62(1), 1-20 (2003).
94. Chan LC, Greenfield PF, Reid S. Optimising fed-batch production of recombinant proteins using the baculovirus expression vector system. Biotechnol. Bioeng. 59(2), 178-188 (1998).
95. Elias CB, Zeiser A, Bédard C, Kamen AA. Enhanced growth of Sf-9 cells to a maximum density of 5.2 x 10(7) cells per mL and production of ?-galactosidase at high cell density by fed batch culture. Biotechnol. Bioeng. 68(4), 381-388 (2000).
96. Bédard C, Perret S, Kamen A. Fed-batch culture of Sf-9 cells supports 3 107 cells per ml and improves baculovirus-expressed recombinant protein yields. Biotechnol. Lett. 19(7), 629-632 (1997).
97. Bernal V, Carinhas N, Yokomizo AY, Carrondo MJ, Alves PM. Cell density effect in the baculovirus-insect cells system: A quantitative analysis of energetic metabolism. Biotechnol. Bioeng. 104(1), 162-180 (2009).
98. Carinhas N, Bernal V, Monteiro F, Carrondo MJ, Oliveira R, Alves PM. Improving baculovirus production at high cell density through manipulation of energy metabolism. Metab. Eng. 12(1), 39-52 (2010).
99. Maranga L, Cruz PE, Aunins JG, Carrondo MJ. Production of core and virus-like particles with baculovirus infected insect cells. Adv. Biochem. Eng. Biotechnol. 74, 183-206 (2002).
100. Wong KT, Peter CH, Greenfield PF, Reid S, Nielsen LK. Low multiplicity infection of insect cells with a recombinant baculovirus: the cell yield concept. Biotechnol. Bioeng. 49(6), 659-666 (1996).
101. Zwart MP, Erro E, van Oers MM, de Visser JA, Vlak JM. Low multiplicity of infection in vivo results in purifying selection against baculovirus deletion mutants. J. Gen. Virol. 89(Pt 5), 1220-1224 (2008).
102. Radford KM, Cavegn C, Bertrand M, Bernard AR, Reid S, Greenfield PF. The indirect effects of multiplicity of infection on baculovirus expressed proteins in insect cells: secreted and non-secreted products. Cytotechnology 24(1), 73-81 (1997).
103. Prel A, Le Gall-Reculé G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis. 51(Suppl. 1), 484-489 (2007).
104. Krammer F, Schinko T, Messner P, Palmberger D, Ferko B, Grabherr R. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J. Virol. Methods 167(1), 17-22 (2010).
105. Roldao A, Carrondo MJ, Alves PM, Oliveira R. Stochastic simulation of protein expression in the baculovirus/insect cells system. Computers Chem. Eng. 32(1-2), 68-77 (2008).
106. Sokolenko S, George S, Wagner A, Tuladhar A, Andrich JM, Aucoin MG. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: benefits and drawbacks. Biotechnol. Adv. 30(3), 766-781 (2012).
107. Vicente T, Mota JP, Peixoto C, Alves PM, Carrondo MJ. Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances. Biotechnol. Adv. 29(6), 869-878 (2011).
108. Pincus S, Boddapati S, Li J, Sadowski T. Release and stability testing programs for a novel virus-like particle vaccine. Biopharm. Int. 23(Suppl. 10), 26-34 (2010).
109. Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol. Bioeng. 109(6), 1443-1460 (2012).
110. Mellado MC, Mena JA, Lopes A et al. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol. Bioeng. 104(4), 674-686 (2009).
111. Roldão A, Mellado MC, Lima JC, Carrondo MJ, Alves PM, Oliveira R. On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered virus-like particles (VLP): the case of rotavirus VLP. PLoS Comput. Biol. 8(2), e1002367 (2012).
112. Harrison RL, Jarvis DL. Transforming lepidopteran insect cells for improved protein processing. Methods Mol. Biol. 388, 341-356 (2007).
113. Jarvis DL, Fleming JA, Kovacs GR, Summers MD, Guarino LA. Use of early baculovirus promoters for continuous expression and efficient processing of foreign gene products in stably transformed lepidopteran cells. Biotechnology (NY) 8(10), 950-955 (1990).
114. Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, Buonaguro L. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. Vaccine 28(39), 6417-6424 (2010).
115. Yang L, Song Y, Li X et al. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: A desirable vaccine component. J. Virol. 86(14), 7662-7676 (2012).
116. Lee JM, Chung HY, Kim KI et al. Synthesis of double-layered rotavirus-like particles using internal ribosome entry site vector system in stably-transformed Drosophila melanogaster. Biotechnol. Lett. 33(1), 41-46 (2011).
117. Yamaji H, Nakamura M, Kuwahara M, Takahashi Y, Katsuda T, Konishi E. Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells. Appl. Microbiol. Biotechnol. doi:10.1007/s00253-012-4371-y (2012) (Epub ahead of print).
118. Farrell PJ, Lu M, Prevost J, Brown C, Behie L, Iatrou K. High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vector. Biotechnol. Bioeng. 60(6), 656-663 (1998).
119. Loomis KH, Yaeger KW, Batenjany MM et al. InsectDirect System: rapid, high-level protein expression and purification from insect cells. J. Struct. Funct. Genomics 6(2-3), 189-194 (2005).
120. Fernandes F, Vidigal J, Dias MM et al. Flipase-mediated cassette exchange in Sf9 insect cells for stable gene expression. Biotechnol. Bioeng. 109(11), 2836-2844 (2012).
121. Turan S, Galla M, Ernst E et al. Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. J. Mol. Biol. 407(2), 193-221 (2011).